Barclays on Medical Supplies & Devices: Continue To Favor Stocks with Potential Product Catalyst (STJ, THOR, HWTR & NUVA)
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Price: $80.82 --0%
Rating Summary:
3 Buy, 21 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
3 Buy, 21 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Barclays on Medical Supplies & Devices: Spring Outlook and March Qtr EPS Review
Analyst, Adam Feinstein, said, "As we await MDT's 5/22 report for a complete picture of several major markets, we view 1Q volumes as relatively stable over modest expectations in the 1Q earnings season. While we see signs of stability and slight improvements in tone, we believe that a step up in utilization in the near term is unlikely as macro and pricing pressures, payer pushback, and challenges in Europe persist."
"In our view, there is not a "quick fix" to the economic drivers that impact medtech market growth including unemployment, insurance coverage, benefit design, scrutiny on overutilization, elective procedure delays, and government and hospital budget constraints. With this as a backdrop, we continue to favor stocks with potential product catalysts (St. Jude (Nasdaq: STJ) / Thoratec (Nasdaq: THOR) / Heartware (Nasdaq: HTWR) / NuVasive (Nasdaq: NUVA)), best relative valuations (Zimmer (NYSE: ZMH)/Covidien (NYSE: COV)), and strong clinical data that support increased utilization. We expect macro challenges to keep a lid on valuations and reiterate our neutral rating on the group."
Analyst, Adam Feinstein, said, "As we await MDT's 5/22 report for a complete picture of several major markets, we view 1Q volumes as relatively stable over modest expectations in the 1Q earnings season. While we see signs of stability and slight improvements in tone, we believe that a step up in utilization in the near term is unlikely as macro and pricing pressures, payer pushback, and challenges in Europe persist."
"In our view, there is not a "quick fix" to the economic drivers that impact medtech market growth including unemployment, insurance coverage, benefit design, scrutiny on overutilization, elective procedure delays, and government and hospital budget constraints. With this as a backdrop, we continue to favor stocks with potential product catalysts (St. Jude (Nasdaq: STJ) / Thoratec (Nasdaq: THOR) / Heartware (Nasdaq: HTWR) / NuVasive (Nasdaq: NUVA)), best relative valuations (Zimmer (NYSE: ZMH)/Covidien (NYSE: COV)), and strong clinical data that support increased utilization. We expect macro challenges to keep a lid on valuations and reiterate our neutral rating on the group."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
- Equinor ASA (EQNR) Tops Q1 EPS by 22c, misses on revenue
- Southern Copper Corp. (SCCO) Tops Q1 EPS by 20c
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
